Last reviewed · How we verify
NCT04972682: SENTRY
[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer
NA trial testing Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy in Endometrial Cancer in 102 participants. Completed in 15 April 2024.
15 August 2023
Quick facts
| Lead sponsor | Moscow City Oncology Hospital No. 62 |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 102 |
| Start date | 1 July 2021 |
| Primary completion | 15 August 2023 |
| Estimated completion | 15 April 2024 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy
Conditions studied
- Endometrial Cancer — all drugs for Endometrial Cancer →
- Endometrial Neoplasms — all drugs for Endometrial Neoplasms →
- Endometrial Adenocarcinoma — all drugs for Endometrial Adenocarcinoma →
- Endometrial Cancer Stage I — all drugs for Endometrial Cancer Stage I →
Sponsor
Moscow City Oncology Hospital No. 62
Who can join
18 and older, female only, with Endometrial Cancer or Endometrial Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
While total hysterectomy without lymph node staging is standard for low- and intermediate-risk endometrial cancer, certain histopathologic factors can necessitate additional interventions. Our study assesses the influence of sentinel lymph node (SLN) biopsy on postoperative decision-making.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tailoring postoperative management through sentinel lymph node biopsy in low- and intermediate-risk endometrial cancer - the SENTRY clinical trial.
Sorokin P, Novozhilov M, Utkin D, Abduragimova Z, et al · · 2024 · PMID 38697821 · DOI 10.48095/ccko2024126
Verify or expand the search:
- PubMed search for NCT04972682
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Cancer
Currently open trials in the same condition.
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
- NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
- NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
- NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04972682 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Moscow City Oncology Hospital No. 62
- Last refreshed: 7 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04972682.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing